CureGenetics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $93.5M
Overview
A clinical-stage biotech developing novel CAR-NKT and AAV gene therapies for solid tumors and genetic diseases.
OncologyRare Disease
Technology Platform
AIMS CAR-NKT platform for engineering NKT cells to target solid tumors, and the VELP™ platform for discovering novel AAV serotypes for targeted gene therapy.
Opportunities
Significant opportunity in the underserved solid tumor immunotherapy market with its CAR-NKT platform, and potential for high-value platform partnerships in gene therapy via its VELP™ AAV technology.
Risk Factors
Clinical and regulatory risks associated with first-in-class CAR-NKT therapy; competitive intensity in the cell/gene therapy space; and execution risks in scaling manufacturing and global development.
Competitive Landscape
Competes with other CAR-T and cell therapy developers in oncology (e.g., Allogene, Caribou) and AAV gene therapy companies. Differentiates via its unique NKT cell platform for solid tumors and its AAV serotype discovery engine for non-liver tissues.